See more : Albertsons Companies, Inc. (ACI) Income Statement Analysis – Financial Results
Complete financial analysis of Chembio Diagnostics, Inc. (CEMI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chembio Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- GrandTech C.G. Systems Inc. (6123.TWO) Income Statement Analysis – Financial Results
- Permex Petroleum Corporation (OILCD) Income Statement Analysis – Financial Results
- Innovation Pharmaceuticals Inc. (IPIX) Income Statement Analysis – Financial Results
- MOBILE INFRASTRUCTURE CORP (MBIC) Income Statement Analysis – Financial Results
- BioPlus Acquisition Corp. (BIOS) Income Statement Analysis – Financial Results
Chembio Diagnostics, Inc. (CEMI)
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.34M | 36.93M | 30.45M | 34.46M | 33.41M | 24.02M | 17.87M | 24.26M | 27.65M | 29.55M | 25.61M | 19.39M | 16.70M | 13.83M | 11.05M | 9.23M | 6.50M | 3.94M | 3.31M | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 38.58M | 34.50M | 23.87M | 22.39M | 21.43M | 12.92M | 9.42M | 13.77M | 16.83M | 17.25M | 14.82M | 10.00M | 8.60M | 7.97M | 7.20M | 5.37M | 4.49M | 2.61M | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.76M | 2.43M | 6.58M | 12.07M | 11.98M | 11.09M | 8.45M | 10.49M | 10.81M | 12.30M | 10.79M | 9.39M | 8.10M | 5.86M | 3.85M | 3.86M | 2.02M | 1.33M | 820.34K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 20.19% | 6.58% | 21.60% | 35.02% | 35.86% | 46.20% | 47.30% | 43.23% | 39.12% | 41.63% | 42.13% | 48.43% | 48.49% | 42.36% | 34.86% | 41.84% | 31.01% | 33.80% | 24.81% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.07M | 12.49M | 9.51M | 8.54M | 8.53M | 8.56M | 8.43M | 6.38M | 4.83M | 5.83M | 4.49M | 4.88M | 2.59M | 2.88M | 2.61M | 1.91M | 1.40M | 1.36M | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.15M | 5.73M | 4.48M | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.28K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 1.78M | 1.01M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.00 | 0.00 | 0.00 |
| SG&A | 24.28M | 24.84M | 21.04M | 16.14M | 11.10M | 9.02M | 7.60M | 7.66M | 7.50M | 5.49M | 4.85M | 3.42M | 2.94M | 2.66M | 3.32M | 4.83M | 5.20M | 3.24M | 2.49M | 3.11K | 45.05K | 6.73K | 128.83K |
| Other Expenses | -1.18M | -10.89M | -2.02M | 0.00 | 0.00 | 0.00 | 0.00 | -4.81K | -5.71K | 7.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.16M | 26.44M | 28.53M | 24.68M | 19.63M | 17.58M | 16.02M | 14.04M | 12.36M | 11.30M | 9.34M | 8.30M | 5.53M | 5.54M | 5.92M | 6.74M | 6.61M | 4.63M | 3.92M | 7.12K | 47.02K | 6.73K | 130.77K |
| Cost & Expenses | 68.74M | 60.93M | 52.40M | 47.07M | 41.05M | 30.50M | 25.44M | 27.81M | 29.20M | 28.54M | 24.16M | 18.30M | 14.13M | 13.52M | 13.12M | 12.11M | 11.10M | 7.24M | 6.41M | 7.12K | 47.02K | 6.73K | 130.77K |
| Interest Income | 0.00 | 0.00 | 0.00 | -846.83K | 49.50K | 25.43K | 25.55K | 2.41K | 5.84K | 5.78K | 7.91K | 6.30K | 4.15K | 9.03K | 34.40K | 145.29K | 29.53K | 39.80K | 8.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 382.00K | 2.91M | 2.84M | -846.83M | 0.00 | 2.95K | 0.00 | 836.00 | 0.00 | 335.00 | 9.50K | 18.62K | 14.73K | 10.60K | 8.32K | 16.88K | 386.90K | 15.68K | 190.56K | 0.00 | 635.00 | 0.00 | 14.00 |
| Depreciation & Amortization | 5.79M | 2.93M | 2.70M | 721.47K | 337.65K | 1.28M | 1.14M | 1.37M | 739.30K | 607.82K | 523.28K | 437.83K | 283.74K | 362.34K | 345.39K | 283.36K | 209.54K | 98.51K | 109.97K | 4.01K | 367.00 | 63.41K | 176.00 |
| EBITDA | -14.61M | -21.07M | -19.25M | -11.89M | -7.31M | -5.18M | -6.41M | -2.18M | -810.82K | 1.63M | 1.45M | 1.53M | 2.86M | 688.70K | -1.69M | -2.71M | -4.33M | -3.20M | -3.18M | -11.62K | -46.65K | 56.67K | -132.51K |
| EBITDA Ratio | -30.23% | -57.07% | -63.23% | -34.49% | -21.87% | -21.57% | -35.86% | -9.00% | -2.93% | 5.50% | 5.67% | 7.90% | 17.13% | 4.98% | -15.30% | -29.40% | -66.58% | -81.19% | -96.20% | 0.00% | 0.00% | 0.00% | -13,251,300.00% |
| Operating Income | -20.40M | -24.01M | -21.95M | -12.61M | -7.65M | -6.48M | -7.57M | -3.55M | -1.55M | 1.00M | 1.45M | 1.09M | 2.57M | 317.33K | -2.07M | -2.88M | -4.60M | -3.30M | -3.10M | -7.12K | -47.02K | -6.73K | -130.77K |
| Operating Income Ratio | -42.21% | -65.01% | -72.08% | -36.58% | -22.88% | -26.99% | -42.37% | -14.65% | -5.61% | 3.40% | 5.67% | 5.61% | 15.41% | 2.29% | -18.74% | -31.16% | -70.68% | -83.69% | -93.87% | 0.00% | 0.00% | 0.00% | -13,076,900.00% |
| Total Other Income/Expenses | 381.80K | -9.96M | -2.84M | -846.83K | 49.50K | 22.49K | 25.55K | -3.24K | 132.00 | 12.94K | -1.58K | -12.33K | -14.50K | -8.27K | 121.90K | 249.27K | -398.83K | 45.99K | 186.90K | 8.51K | 0.00 | -63.41K | 1.92K |
| Income Before Tax | -23.26M | -33.97M | -25.98M | -14.18M | -7.93M | -6.46M | -7.55M | -3.56M | -1.55M | 1.02M | 1.45M | 1.08M | 2.56M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -2.92M | 1.39K | 0.00 | -70.14K | -128.85K |
| Income Before Tax Ratio | -48.11% | -91.98% | -85.31% | -41.13% | -23.75% | -26.90% | -42.23% | -14.67% | -5.61% | 3.44% | 5.66% | 5.55% | 15.32% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -88.22% | 0.00% | 0.00% | 0.00% | -12,884,900.00% |
| Income Tax Expense | 34.41K | -62.05K | -456.79K | -500.29K | -67.52K | -88.31K | 5.80M | -1.16M | -412.92K | 486.95K | 509.24K | -5.13M | 45.82K | 10.60K | 8.32K | -249.27K | 398.83K | -24.12K | -4.47K | -8.51K | 635.00 | 2.67K | -1.91K |
| Net Income | -23.29M | -33.90M | -25.52M | -13.68M | -7.87M | -6.37M | -13.35M | -2.40M | -1.14M | 530.82K | 941.28K | 6.21M | 2.51M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -3.10M | 1.39K | -47.65K | -72.82K | -128.86K |
| Net Income Ratio | -48.18% | -91.81% | -83.81% | -39.68% | -23.54% | -26.53% | -74.69% | -9.88% | -4.11% | 1.80% | 3.68% | 32.02% | 15.05% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -93.74% | 0.00% | 0.00% | 0.00% | -12,886,400.00% |
| EPS | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.12 | 0.79 | 0.32 | 0.04 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| EPS Diluted | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.11 | 0.73 | 0.32 | 0.03 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| Weighted Avg Shares Out | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 8.99M | 7.99M | 7.87M | 7.76M | 7.74M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
| Weighted Avg Shares Out (Dil) | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 9.52M | 8.61M | 8.56M | 8.87M | 9.38M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
DPP approves charges against ex-KPA boss Manduku after push and pull with DCI
NAIROBI, Kenya, Aug 27- Former Managing Director of the Kenya Ports Authority Daniel Manduku will finally face charges over Sh244 million scandal after a protracted stand-off between investigators and prosecutors. Manduku was first arrested in March by detectives from the...
Skoda Rapid TSI automatic bookings open now, launch in September
The pre-booked Skoda Rapid TSI automatic units will be delivered to customers from 18 September 2020.
PKB Jateng menunggu rekomendasi Pilkada Kota Magelang dan Kendal
Ketua Dewan Pengurus Wilayah Partai Kebangkitan Bangsa Jawa Tengah KH. Muhammad Yusuf Chudlori mengatakan pihaknya masih menunggu rekomendasi dari ...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or...
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Chembio Diagnostics, Inc.
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP reminds Chembio Diagnostics, Inc. (NASDAQ: CEMI) (“Chembio”) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Chembio...
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Chembio Diagnostics, Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of...
CEMI UPCOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Chembio Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. ("Chembio" or "the Company") (NASDAQ: CEMI) and certain of its officers, on behalf of shareholders who purchased or otherwise...
PDIP umumkan calon wali kota Surabaya paling lambat 19 Agustus
PDI Perjuangan akan mengumumkan pasangan calon wali kota dan calon wakil wali kota Surabaya paling lambat 19 Agustus 2020. “Ada empat tahap ...
CEMI UPCOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Chembio Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. (
Guan Eng Trial Live Updates: Pleads not guilty to soliciting RM3.3m bribe
BUTTERWORTH: Lim Guan Eng has pleaded not guilty to a charge of using his position as then chief minister of Penang to solicit a RM3.3mil bribe related to the RM6.3bil Penang undersea tunnel project.
Source: https://incomestatements.info
Category: Stock Reports